Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Ladenburg starts CA Healthcare Acquisition at Buy ahead of LumiraDx deal » 06:50
08/31/21
08/31
06:50
08/31/21
06:50
CAHC

CA Healthcare Acquisition

$9.90 /

+0.02 (+0.20%)

, LMDX

LumiraDx

/

+

Ladenburg Thalmann…

Ladenburg Thalmann analyst Jeffrey Cohen initiated coverage of CA Healthcare Acquisition (CAHC) with a Buy rating and $14.75 price target. The company has entered into a definitive agreement merger agreement with LumiraDx (LMDX), which the analyst anticipates could occur during late Q3 to early Q4 of this year. Cohen says the combined company should be valued in comparison with other "innovative" medical technology and diagnostic companies.

ShowHide Related Items >><<
CAHC CA Healthcare Acquisition
$9.90 /

+0.02 (+0.20%)

CAHC CA Healthcare Acquisition
$9.90 /

+0.02 (+0.20%)

08/31/21 Ladenburg
CA Healthcare Acquisition initiated with a Buy at Ladenburg
LMDX LumiraDx
/

+

CAHC CA Healthcare Acquisition
$9.90 /

+0.02 (+0.20%)

Initiation
CA Healthcare Acquisition initiated with a Buy at Ladenburg » 06:34
08/31/21
08/31
06:34
08/31/21
06:34
CAHC

CA Healthcare Acquisition

$9.90 /

+0.02 (+0.20%)

Ladenburg analyst Jeffrey…

Ladenburg analyst Jeffrey Cohen initiated coverage of CA Healthcare Acquisition with a Buy rating and $14 price target.

ShowHide Related Items >><<
CAHC CA Healthcare Acquisition
$9.90 /

+0.02 (+0.20%)

CAHC CA Healthcare Acquisition
$9.90 /

+0.02 (+0.20%)

Over a month ago
Hot Stocks
LumiraDx, CA Healthcare Acquisition revise transaction terms » 08:06
08/20/21
08/20
08:06
08/20/21
08:06
CAHC

CA Healthcare Acquisition

$9.89 /

+ (+0.00%)

LumiraDx and CA…

LumiraDx and CA Healthcare Acquisition announced they have revised the valuation of their previously announced transaction based on various considerations, including the recent market environment for publicly traded diagnostic companies, general market declines in COVID-19 testing volumes, and feedback from CA Healthcare advisors and shareholders. LumiraDx's progress in rolling out its transformational platform, signing up customers in key geographies and expanding its testing menu, combined with the adjusted valuation, supports a highly compelling investment thesis for driving long-term shareholder value. The new transaction terms adjust the pro forma enterprise value of LumiraDx from $5B to $3B excluding any cash held in trust by CAHC. As previously announced, the combined group is expected to receive approximately $115M of cash held in trust, assuming no redemptions of CAHC's existing public stockholders. Upon closing of the transaction, LumiraDx's common shares are expected to trade on Nasdaq under the ticker symbol (LMDX). The transaction is currently expected to close in the fall of this year, subject to approval by the security holders of each of CAHC and LumiraDx and the satisfaction of customary closing conditions. As previously stated, current LumiraDx shareholders will retain the entirety of their existing holdings in LumiraDx. The additional capital from CAHC's cash held in trust, after any redemptions, together with cash from operations will provide growth capital to support increasing production, continued R&D activities and commercial and manufacturing expansion.

ShowHide Related Items >><<
CAHC CA Healthcare Acquisition
$9.89 /

+ (+0.00%)

CAHC CA Healthcare Acquisition
$9.89 /

+ (+0.00%)

Conference/Events
CA Healthcare Acquisition management to meet virtually with BTIG » 04:55
07/29/21
07/29
04:55
07/29/21
04:55
CAHC

CA Healthcare Acquisition

$9.85 /

+ (+0.00%)

Virtual Meetings to be…

Virtual Meetings to be held on July 27-29 hosted by BTIG.

ShowHide Related Items >><<
CAHC CA Healthcare Acquisition
$9.85 /

+ (+0.00%)

CAHC CA Healthcare Acquisition
$9.85 /

+ (+0.00%)

Conference/Events
CA Healthcare Acquisition management to meet virtually with BTIG » 10:46
07/28/21
07/28
10:46
07/28/21
10:46
CAHC

CA Healthcare Acquisition

$9.85 /

+ (+0.00%)

Virtual Meetings to be…

Virtual Meetings to be held on July 27-29 hosted by BTIG.

ShowHide Related Items >><<
CAHC CA Healthcare Acquisition
$9.85 /

+ (+0.00%)

CAHC CA Healthcare Acquisition
$9.85 /

+ (+0.00%)

Over a quarter ago
Conference/Events
CA Healthcare Acquisition management to meet virtually with » 12:00
04/09/21
04/09
12:00
04/09/21
12:00
CAHC

CA Healthcare Acquisition

$10.02 /

+0.03 (+0.30%)

Virtual Meeting to be…

Virtual Meeting to be held

ShowHide Related Items >><<
CAHC CA Healthcare Acquisition
$10.02 /

+0.03 (+0.30%)

CAHC CA Healthcare Acquisition
$10.02 /

+0.03 (+0.30%)

On The Fly
Fly Intel: Wall Street's top stories for Wednesday » 16:38
04/07/21
04/07
16:38
04/07/21
16:38
AMZN

Amazon.com

$3,280.07 /

+54.68 (+1.70%)

, CCL

Carnival

$28.99 /

+0.39 (+1.36%)

, CAHC

CA Healthcare Acquisition

$10.01 /

+0.36 (+3.73%)

, XOM

Exxon Mobil

$56.59 /

+0.25 (+0.44%)

, OUST

Ouster

$9.85 /

+2.02 (+25.80%)

, BHVN

Biohaven Pharmaceutical

$71.27 /

+5.67 (+8.64%)

, FGEN

FibroGen

$19.75 /

-14.87 (-42.95%)

, GEO

Geo Group

$6.21 /

-1.6 (-20.49%)

, AZN

AstraZeneca

$48.44 /

-0.78 (-1.58%)

Equities had a day of…

ShowHide Related Items >><<
XOM Exxon Mobil
$56.59 /

+0.25 (+0.44%)

OUST Ouster
$9.85 /

+2.02 (+25.80%)

GEO Geo Group
$6.21 /

-1.6 (-20.49%)

FGEN FibroGen
$19.75 /

-14.87 (-42.95%)

CCL Carnival
$28.99 /

+0.39 (+1.36%)

CAHC CA Healthcare Acquisition
$10.01 /

+0.36 (+3.73%)

BHVN Biohaven Pharmaceutical
$71.27 /

+5.67 (+8.64%)

AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

AMZN Amazon.com
$3,280.07 /

+54.68 (+1.70%)

AMZN Amazon.com
$3,280.07 /

+54.68 (+1.70%)

04/05/21 Evercore ISI
Amazon.com assumed with an Outperform at Evercore ISI
04/01/21 Wedbush
Microsoft gets another major win within the beltway, says Wedbush
04/01/21 Credit Suisse
Ubiquiti price target lowered to $126 from $157 at Credit Suisse
03/31/21 Wolfe Research
Amazon.com assumed with an Outperform at Wolfe Research
CCL Carnival
$28.99 /

+0.39 (+1.36%)

04/08/21 Deutsche Bank
Carnival price target raised to $25 from $16 at Deutsche Bank
04/08/21 Stifel
Carnival price target raised to $35 from $30 at Stifel
04/07/21 William Blair
Carnival stock already pricing in recovery, says William Blair
04/01/21 Citi
Carnival initiated with a Buy at Citi
CAHC CA Healthcare Acquisition
$10.01 /

+0.36 (+3.73%)

XOM Exxon Mobil
$56.59 /

+0.25 (+0.44%)

04/06/21 Goldman Sachs
Chevron downgraded to Neutral from Buy at Goldman Sachs
03/08/21 UBS
Exxon Mobil price target raised to $59 from $48 at UBS
03/05/21 DZ Bank
Exxon Mobil upgraded to Hold from Sell at DZ Bank
03/04/21 MKM Partners
Exxon Mobil price target raised to $60 from $56 at MKM Partners
OUST Ouster
$9.85 /

+2.02 (+25.80%)

04/07/21 Citi
Ouster initiated with a Buy at Citi
BHVN Biohaven Pharmaceutical
$71.27 /

+5.67 (+8.64%)

04/01/21 Piper Sandler
Piper migraine survey bearish for Amgen, bullish for Biohaven
03/11/21
Fly Intel: Top five analyst initiations
03/11/21 UBS
Biohaven Pharmaceutical initiated with a Buy at UBS
03/02/21 Mizuho
Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho
FGEN FibroGen
$19.75 /

-14.87 (-42.95%)

04/07/21
Fly Intel: Top five analyst downgrades
04/07/21 Mizuho
Mizuho downgrades FibroGen to Neutral on 'higher risk and uncertainty'
04/07/21 Mizuho
FibroGen downgraded to Neutral from Buy at Mizuho
04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
GEO Geo Group
$6.21 /

-1.6 (-20.49%)

06/29/20 Noble Capital
Geo Group initiated with an Outperform at Noble Capital
AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
XOM Exxon Mobil
$56.59 /

+0.25 (+0.44%)

GEO Geo Group
$6.21 /

-1.6 (-20.49%)

FGEN FibroGen
$19.75 /

-14.87 (-42.95%)

CCL Carnival
$28.99 /

+0.39 (+1.36%)

BHVN Biohaven Pharmaceutical
$71.27 /

+5.67 (+8.64%)

AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

AMZN Amazon.com
$3,280.07 /

+54.68 (+1.70%)

  • 16
    Mar
  • 23
    Feb
XOM Exxon Mobil
$56.59 /

+0.25 (+0.44%)

GEO Geo Group
$6.21 /

-1.6 (-20.49%)

CCL Carnival
$28.99 /

+0.39 (+1.36%)

AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

AMZN Amazon.com
$3,280.07 /

+54.68 (+1.70%)

XOM Exxon Mobil
$56.59 /

+0.25 (+0.44%)

OUST Ouster
$9.85 /

+2.02 (+25.80%)

FGEN FibroGen
$19.75 /

-14.87 (-42.95%)

CCL Carnival
$28.99 /

+0.39 (+1.36%)

CAHC CA Healthcare Acquisition
$10.01 /

+0.36 (+3.73%)

BHVN Biohaven Pharmaceutical
$71.27 /

+5.67 (+8.64%)

AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

AMZN Amazon.com
$3,280.07 /

+54.68 (+1.70%)

XOM Exxon Mobil
$56.59 /

+0.25 (+0.44%)

OUST Ouster
$9.85 /

+2.02 (+25.80%)

GEO Geo Group
$6.21 /

-1.6 (-20.49%)

FGEN FibroGen
$19.75 /

-14.87 (-42.95%)

CCL Carnival
$28.99 /

+0.39 (+1.36%)

AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

AMZN Amazon.com
$3,280.07 /

+54.68 (+1.70%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:26
04/07/21
04/07
12:26
04/07/21
12:26
AMZN

Amazon.com

$3,287.62 /

+62.23 (+1.93%)

, CCL

Carnival

$29.33 /

+0.73 (+2.55%)

, CAHC

CA Healthcare Acquisition

$10.05 /

+0.4 (+4.15%)

, OUST

Ouster

$9.75 /

+1.92 (+24.52%)

, BHVN

Biohaven Pharmaceutical

$72.25 /

+6.65 (+10.14%)

, FGEN

FibroGen

$20.86 /

-13.765 (-39.76%)

, GEO

Geo Group

$6.24 /

-1.57 (-20.10%)

Equity futures were…

ShowHide Related Items >><<
OUST Ouster
$9.75 /

+1.92 (+24.52%)

GEO Geo Group
$6.24 /

-1.57 (-20.10%)

FGEN FibroGen
$20.86 /

-13.765 (-39.76%)

CCL Carnival
$29.33 /

+0.73 (+2.55%)

CAHC CA Healthcare Acquisition
$10.05 /

+0.4 (+4.15%)

BHVN Biohaven Pharmaceutical
$72.25 /

+6.65 (+10.14%)

AMZN Amazon.com
$3,287.62 /

+62.23 (+1.93%)

AMZN Amazon.com
$3,287.62 /

+62.23 (+1.93%)

04/05/21 Evercore ISI
Amazon.com assumed with an Outperform at Evercore ISI
04/01/21 Wedbush
Microsoft gets another major win within the beltway, says Wedbush
04/01/21 Credit Suisse
Ubiquiti price target lowered to $126 from $157 at Credit Suisse
03/31/21 Wolfe Research
Amazon.com assumed with an Outperform at Wolfe Research
CCL Carnival
$29.33 /

+0.73 (+2.55%)

04/07/21 William Blair
Carnival stock already pricing in recovery, says William Blair
04/01/21 Citi
Carnival initiated with a Buy at Citi
03/24/21 Stifel
Cruiseline stock selloff 'unwarranted,' says Stifel
03/18/21
Fly Intel: Top five analyst upgrades
CAHC CA Healthcare Acquisition
$10.05 /

+0.4 (+4.15%)

OUST Ouster
$9.75 /

+1.92 (+24.52%)

04/07/21 Citi
Ouster initiated with a Buy at Citi
BHVN Biohaven Pharmaceutical
$72.25 /

+6.65 (+10.14%)

04/01/21 Piper Sandler
Piper migraine survey bearish for Amgen, bullish for Biohaven
03/11/21
Fly Intel: Top five analyst initiations
03/11/21 UBS
Biohaven Pharmaceutical initiated with a Buy at UBS
03/02/21 Mizuho
Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho
FGEN FibroGen
$20.86 /

-13.765 (-39.76%)

04/07/21
Fly Intel: Top five analyst downgrades
04/07/21 Mizuho
Mizuho downgrades FibroGen to Neutral on 'higher risk and uncertainty'
04/07/21 Mizuho
FibroGen downgraded to Neutral from Buy at Mizuho
04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
GEO Geo Group
$6.24 /

-1.57 (-20.10%)

06/29/20 Noble Capital
Geo Group initiated with an Outperform at Noble Capital
GEO Geo Group
$6.24 /

-1.57 (-20.10%)

FGEN FibroGen
$20.86 /

-13.765 (-39.76%)

CCL Carnival
$29.33 /

+0.73 (+2.55%)

BHVN Biohaven Pharmaceutical
$72.25 /

+6.65 (+10.14%)

AMZN Amazon.com
$3,287.62 /

+62.23 (+1.93%)

  • 16
    Mar
  • 23
    Feb
GEO Geo Group
$6.24 /

-1.57 (-20.10%)

CCL Carnival
$29.33 /

+0.73 (+2.55%)

AMZN Amazon.com
$3,287.62 /

+62.23 (+1.93%)

OUST Ouster
$9.75 /

+1.92 (+24.52%)

FGEN FibroGen
$20.86 /

-13.765 (-39.76%)

CCL Carnival
$29.33 /

+0.73 (+2.55%)

CAHC CA Healthcare Acquisition
$10.05 /

+0.4 (+4.15%)

BHVN Biohaven Pharmaceutical
$72.25 /

+6.65 (+10.14%)

AMZN Amazon.com
$3,287.62 /

+62.23 (+1.93%)

OUST Ouster
$9.75 /

+1.92 (+24.52%)

GEO Geo Group
$6.24 /

-1.57 (-20.10%)

FGEN FibroGen
$20.86 /

-13.765 (-39.76%)

CCL Carnival
$29.33 /

+0.73 (+2.55%)

AMZN Amazon.com
$3,287.62 /

+62.23 (+1.93%)

On The Fly
Fly Intel: Pre-market Movers » 08:57
04/07/21
04/07
08:57
04/07/21
08:57
CAHC

CA Healthcare Acquisition

$9.65 /

+ (+0.00%)

, TMDX

TransMedics

$34.41 /

+0.1 (+0.29%)

, HYLN

Hyliion Holdings

$10.86 /

+0.11 (+1.02%)

, HIMX

Himax

$14.44 /

+0.25 (+1.76%)

, SMPL

Simply Good Foods

$31.21 /

-0.17 (-0.54%)

, MSM

MSC Industrial

$91.77 /

-0.065 (-0.07%)

, RPM

RPM

$94.30 /

+0.21 (+0.22%)

, FGEN

FibroGen

$34.61 /

-0.93 (-2.62%)

, FIXX

Homology Medicines

$9.30 /

-0.34 (-3.53%)

, UPST

Upstart

$143.99 /

+3.03 (+2.15%)

Check out this morning's…

ShowHide Related Items >><<
UPST Upstart
$143.99 /

+3.03 (+2.15%)

TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

SMPL Simply Good Foods
$31.21 /

-0.17 (-0.54%)

RPM RPM
$94.30 /

+0.21 (+0.22%)

MSM MSC Industrial
$91.77 /

-0.065 (-0.07%)

HYLN Hyliion Holdings
$10.86 /

+0.11 (+1.02%)

HIMX Himax
$14.44 /

+0.25 (+1.76%)

FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

CAHC CA Healthcare Acquisition
$9.65 /

+ (+0.00%)

CAHC CA Healthcare Acquisition
$9.65 /

+ (+0.00%)

TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

04/07/21 Canaccord
TransMedics label likely more limited than expected, says Canaccord
03/29/21 Cowen
TransMedics price target raised to $49 from $44 at Cowen
03/15/21 Canaccord
TransMedics price target raised to $79 from $46 at Canaccord
03/03/21 Morgan Stanley
TransMedics price target raised to $38 from $16 at Morgan Stanley
HYLN Hyliion Holdings
$10.86 /

+0.11 (+1.02%)

03/18/21 UBS
Hyliion Holdings initiated with a Neutral at UBS
02/02/21 Goldman Sachs
Hyliion Holdings downgraded to Sell from Neutral at Goldman Sachs
12/16/20 Barclays
Hyliion Holdings initiated with an Overweight at Barclays
10/28/20
Fly Intel: Top five analyst initiations
HIMX Himax
$14.44 /

+0.25 (+1.76%)

03/09/21 Vertical Group
Himax reinstated with a Neutral at Vertical Group
02/08/21 Northland
Himax price target raised to $13 from $4.50 at Northland
01/27/21 Nomura
Himax upgraded to Buy from Neutral at Nomura
11/30/20 Baird
Himax price target raised to $11 from $8 at Baird
SMPL Simply Good Foods
$31.21 /

-0.17 (-0.54%)

04/06/21 Credit Suisse
Simply Good Foods initiated with a Neutral at Credit Suisse
03/19/21 Jefferies
Simply Good Foods downgraded to Hold on valuation at Jefferies
03/19/21 Jefferies
Simply Good Foods downgraded to Hold from Buy at Jefferies
02/03/21 DA Davidson
Simply Good Foods downgraded to Neutral from Buy at DA Davidson
MSM MSC Industrial
$91.77 /

-0.065 (-0.07%)

04/05/21 Deutsche Bank
MSC Industrial price target lowered to $89 from $90 at Deutsche Bank
01/07/21 Wells Fargo
MSC Industrial price target raised to $90 from $80 at Wells Fargo
12/31/20 William Blair
Azek, Trex among Blair's top Specialty Distribution ideas for 2021
12/16/20 Deutsche Bank
MSC Industrial price target raised to $92 from $75 at Deutsche Bank
RPM RPM
$94.30 /

+0.21 (+0.22%)

03/04/21 Vertical Research
RPM upgraded to Buy from Hold at Vertical Research
01/08/21 RBC Capital
RPM downgraded to Sector Perform from Outperform at RBC Capital
01/07/21 BMO Capital
RPM price target raised to $113 from $109 at BMO Capital
12/14/20 Morgan Stanley
RPM downgraded to Equal Weight from Overweight at Morgan Stanley
FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

04/07/21 Mizuho
Mizuho downgrades FibroGen to Neutral on 'higher risk and uncertainty'
04/07/21 Mizuho
FibroGen downgraded to Neutral from Buy at Mizuho
04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
04/07/21 H.C. Wainwright
FibroGen downgraded to Neutral from Buy at H.C. Wainwright
FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
UPST Upstart
$143.99 /

+3.03 (+2.15%)

03/22/21 Barclays
Upstart price target raised to $110 from $58 at Barclays
03/18/21 BofA
Upstart upgraded to Buy on accelerating growth at BofA
03/18/21 BofA
Upstart upgraded to Buy from Neutral at BofA
03/18/21
Fly Intel: Top five analyst upgrades
UPST Upstart
$143.99 /

+3.03 (+2.15%)

TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

SMPL Simply Good Foods
$31.21 /

-0.17 (-0.54%)

RPM RPM
$94.30 /

+0.21 (+0.22%)

MSM MSC Industrial
$91.77 /

-0.065 (-0.07%)

HYLN Hyliion Holdings
$10.86 /

+0.11 (+1.02%)

HIMX Himax
$14.44 /

+0.25 (+1.76%)

FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

  • 09
    Apr
  • 07
    Apr
  • 16
    Dec
  • 27
    May
HYLN Hyliion Holdings
$10.86 /

+0.11 (+1.02%)

UPST Upstart
$143.99 /

+3.03 (+2.15%)

TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

SMPL Simply Good Foods
$31.21 /

-0.17 (-0.54%)

RPM RPM
$94.30 /

+0.21 (+0.22%)

HIMX Himax
$14.44 /

+0.25 (+1.76%)

FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

CAHC CA Healthcare Acquisition
$9.65 /

+ (+0.00%)

UPST Upstart
$143.99 /

+3.03 (+2.15%)

HYLN Hyliion Holdings
$10.86 /

+0.11 (+1.02%)

HIMX Himax
$14.44 /

+0.25 (+1.76%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

Hot Stocks
LumiraDx to become publicly traded through CA Healthcare Acquisition merger » 05:36
04/07/21
04/07
05:36
04/07/21
05:36
CAHC

CA Healthcare Acquisition

$9.65 /

+ (+0.00%)

CA Healthcare Acquisition…

CA Healthcare Acquisition announced a definitive merger agreement with LumiraDx, a point of care diagnostics testing company. The combination reflects a value of $5B for Lumira's existing equity, before giving effect to the transaction. Since its founding, LumiraDx has raised $700M in equity capital. LumiraDx has developed its high sensitivity antigen test for COVID-19 on the LumiraDx Platform. The test is currently being used in the UK, the U.S., in Italy, other parts of Europe and is being deployed in partnership with the Bill and Melinda Gates Foundation in a growing number of African countries where access to laboratory diagnostics is limited. The LumiraDx COVID-19 antigen test has received Emergency Use Authorization from the FDA and achieved CE Mark. The LumiraDx Platform and COVID-19 antigen tests are also available in Japan and Brazil and being rolled out in more than 60 countries globally. The combined company will be led by existing CEO Ron Zwanziger and the other co-Founders, and LumiraDx's existing board and governance principles will not change. Upon closing of the transaction, LumiraDx and its common shares are expected to trade on Nasdaq under the ticker symbol (LMDX). The transaction is currently expected to close late Q2, early Q3 this year, subject to approval by the securityholders of each of CAHC and LumiraDx and satisfaction of customary closing conditions. The transaction has been unanimously approved by the board of directors of both LumiraDx and CA Healthcare Acquisition Corp.

ShowHide Related Items >><<
CAHC CA Healthcare Acquisition
$9.65 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.